masoprocol and Bone Loss, Osteoclastic

masoprocol has been researched along with Bone Loss, Osteoclastic in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kukita, A; Kukita, T; Li, YJ; Ninomiya, Y; Qu, P; Sanematsu, K; Takano, T; Watanabe, T1
Bonewald, LF; Gallwitz, WE; Gaskell, SJ; Lee, CH; Mundy, GR; Qiao, M; Raftery, M; Roodman, GD1

Other Studies

2 other study(ies) available for masoprocol and Bone Loss, Osteoclastic

ArticleYear
Nordihydroguaiaretic acid inhibition of NFATc1 suppresses osteoclastogenesis and arthritis bone destruction in rats.
    Laboratory investigation; a journal of technical methods and pathology, 2012, Volume: 92, Issue:12

    Topics: Animals; Arthritis, Experimental; Bone Resorption; Calcium Signaling; Cell Differentiation; Cell Line; Dose-Response Relationship, Drug; Female; Male; Masoprocol; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Osteitis; Osteoclasts; RANK Ligand; Rats; Rats, Sprague-Dawley

2012
5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices.
    The Journal of biological chemistry, 1993, May-15, Volume: 268, Issue:14

    Topics: Acid Phosphatase; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acids; Bone Matrix; Bone Resorption; Chickens; Culture Media, Conditioned; Endopeptidases; Female; Flurbiprofen; Humans; Hydroxyeicosatetraenoic Acids; Indomethacin; Leukotrienes; Lipoxygenase Inhibitors; Masoprocol; Osteoclasts; Tartrates; Ultraviolet Rays

1993